Viridian Therapeutics shares fell after rival Amgen posted positive results for its eye-disease treatment, Tepezza.
The stock fell 21% to $14.73, extending some declines seen since reporting its own eye-treatment results March 30. Shares have fallen by more than 50% year to date.
Amgen's Tepezza showed a 77% response rate in patients partaking in a 24-week Phase 3 study.
The results come after Viridian posted results for its own thyroid eye treatment, Elegrobart, reporting a 51% overall responder rate among patients who were treated, versus 16% among the placebo group.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.